B. Riley Wealth Advisors’s Heron Therapeutics HRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.27K Sell
12,103
-14
-0.1% -$11 ﹤0.01% 912
2026
Q1
$9.04K Hold
12,117
﹤0.01% 876
2025
Q4
$15.8K Hold
12,117
﹤0.01% 1009
2025
Q3
$15.3K Sell
12,117
-373
-3% -$591 ﹤0.01% 1046
2025
Q2
$25.9K Buy
+12,490
New +$25.5K ﹤0.01% 1011
2024
Q4
$19.3K Hold
12,602
﹤0.01% 1131
2024
Q3
$26.1K Buy
12,602
+1,000
+9% +$2.39K ﹤0.01% 1248
2024
Q2
$40.6K Buy
+11,602
New +$35.6K ﹤0.01% 1351
2024
Q1
Sell
-11,490
Closed -$19.5K 1480
2023
Q4
$19.5K Buy
+11,490
New +$12.7K ﹤0.01% 1372
2019
Q2
Sell
-30,686
Closed -$750K 807
2019
Q1
$750K Buy
30,686
+150
+0.5% +$3.93K 0.09% 237
2018
Q4
$793K Sell
30,536
-6,116
-17% -$168K 0.11% 192
2018
Q3
$1.16M Buy
36,652
+6,266
+21% +$233K 0.14% 166
2018
Q2
$1.18M Sell
30,386
-10,300
-25% -$328K 0.16% 156
2018
Q1
$1.12M Sell
40,686
-51,200
-56% -$1.16M 0.16% 153
2017
Q4
$1.66M Buy
91,886
+23,310
+34% +$380K 0.22% 120
2017
Q3
$1.11M Buy
68,576
+21,700
+46% +$340K 0.18% 134
2017
Q2
$650K Buy
+46,876
New +$679K 0.12% 208
2015
Q1
Sell
-1,077
Closed -$11 1197
2014
Q4
$11 Buy
+1,077
New +$8.79K ﹤0.01% 2815
2014
Q3
Sell
-1,077
Closed -$13.3K 1195
2014
Q2
$13.3K Buy
+1,077
New +$12.9K ﹤0.01% 1657

Other funds holding HRTX

B. Riley Wealth Advisors's HRTX Position: Q2 2026 in Review

B. Riley Wealth Advisors reduced its Heron Therapeutics (HRTX) stake by 0.12% in Q2 2026, selling an estimated $11 and leaving 12,103 shares worth $5.27K. The position accounts for ﹤0.01% of the portfolio, ranked #912.

B. Riley Wealth Advisors first reported a position in HRTX in Q2 2014 and has held it in 19 quarters since. The position peaked at $1.66M in Q4 2017. 14 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • B. Riley Wealth Advisors held 12,103 shares of Heron Therapeutics worth $5.27K as of Q2 2026.
  • B. Riley Wealth Advisors sold 14 Heron Therapeutics shares in Q2 2026, an estimated $11.
  • Heron Therapeutics made up ﹤0.01% of B. Riley Wealth Advisors's portfolio in Q2 2026, its #912 holding.
  • B. Riley Wealth Advisors first reported a position in Heron Therapeutics in Q2 2014 and has held it in 19 quarters since.
  • B. Riley Wealth Advisors's Heron Therapeutics position peaked at $1.66M in Q4 2017.
  • 14 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.